Young-adulthood insulin resistance (IR) was linked to a 1.50-fold higher risk of atherosclerotic cardiovascular disease (ASCVD) later in life. Midlife metabolic syndrome (MetS) mediated 63.4% of this association. The analysis included 3,622 Black and White participants in the US CARDIA study. They were aged 18–30 at baseline and free of ASCVD through year 20. IR was defined as a Homeostatic Model Assessment of Insulin Resistance value ≥2.67 (75th percentile). MetS was assessed at year 20, and ASCVD events were ascertained through year 35. Parametric g-computation with pooled logistic regression estimated total and mediated effects on cumulative ASCVD risk. Midlife lifestyle factors were treated as exposure-induced mediator-outcome confounders. At baseline, 907 participants (25%) had IR. During a median follow-up of 14 years after year 20, 143 participants (3.9%) had an ASCVD event. The indirect risk ratio through midlife MetS was 1.29. These findings suggest that early identification of IR and prevention of progression to MetS may help reduce long-term cardiovascular risk. Source: https://www.jacc.org/
